Aravind Asokan
NIH Rank #606
- Program Leader
- Top 5% Funded
- R01 Holder
- Multi-Institutional
- Early Career
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 8605473Search this ID in NIH RePORTER
- ScienceDex PI coverage
- FY2024 through FY2026Career claims are limited to the years shown.
FY2026 award categories
- Surgery
- Pediatrics
NIH Funding · FY2025
Linked Award Amount
$8.2M
Full award amounts, FY2025
Award Records
7
Records listing this PI
Award-Linked Rank
#606
By linked amount among FY2025 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2025 award records by amount
NIH award records listing Aravind Asokan as a PI. Multi-PI records show the full award amount for context.
- $3.2Maward amount
- 4R01AI166969-04R01Evolving Novel AAV Vectors for Gene Therapy to Cure HIV$1.9Maward amount
- $860Kaward amount
- $706.7Kaward amount
- $616.2Kaward amount
- 5U01AI170064-04U01Genetic engineering of kidney allografts by ex vivo perfusion delivery of adeno-associated viral vectors$469.8Kaward amount
- $457Kaward amount
Award organizations
Organizations that administered FY2025 awards listing Aravind Asokan as a PI.
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardDuke University
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2024$2M Cumulative Funding
- 2024Entered Top 50% NationallyRanked #2318
- 2024Entered Top 25% NationallyRanked #2318
- 2025$5M Cumulative Funding
- 2025$10M Cumulative Funding
- 2025Entered Top 10% NationallyRanked #606
- 2025Entered Top 5% NationallyRanked #606
- 2025Multi-Institutional ResearchAwards at 3 institutions
- 2025R01 Grant Holder
- 2025Program/Center Grant Leader
Shared-award investigators
Other investigators listed on at least one of the same NIH award records as Aravind Asokan.